New drug target identified for glioblastoma treatment
Researchers at the National Institute for Basic Biology (Okazaki, Japan) demonstrated that the enzymatic activity of R5 receptor-type protein tyrosine phosphatases is a requisite for the maintenance of stem cell properties and tumorigenicity in glioblastoma cells and could be a promising drug target for treatment.
Please sign in or register for FREE to view this content
Sign in to MedChemNet
Register to MedChemNet – the medicinal chemistry network
MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.